Neurology Updates
All the atest articles, research and news from worlds leading Neurology Journals. Discussion group https://t.me/Professional_Medical_Discussion
- 24 hours
- +12
- 7 days
- +80
- 30 days
- –
- Reactions
- 0
- Reposts
- 1
- Comments
- 0
Subscriber growth
Neurology Updates has 16,751 subscribers. A typical post is seen by about 517 people within a day, an engagement rate of 3.1%.
Daily numbers, last 30 days
| Date | Subscribers | Change | Posts | Avg. post views |
|---|---|---|---|---|
| 11 Nov | 16,751 | +12 | 2 | 362 |
| 10 Nov | 16,739 | +6 | 1 | 549 |
| 9 Nov | 16,733 | +6 | 5 | 532 |
| 8 Nov | 16,727 | +56 | 0 | – |
| 3 Nov | 16,671 | +241 | 1 | 761 |
| 4 Oct | 16,430 | – | 0 | – |
Views as a post ages
Average views at each age, posts of the last 30 days.
- 48 h
- 525
- 7 days
- 771
When it posts
Times in UTC. 28 posts in 90 days.
Recent posts
-
Neurology | Research update — 11 November 2026 Bepranemab fails to slow clinical decline in early Alzheimer disease Phase 2 RCT (466 participants): neither dose improved the primary clinical endpoint at 80 weeks. Favorable biomarker findings remain exploratory. Abstract reviewed. Lancet Neurol • 2026-11-10 Original article: https://doi.org/10.1016/S1474-4422(26)00357-1 Azetukalner reduces drug-resistant focal seizures in X-TOLE2 X-TOLE2 phase 3 (374 adults): median seizure reductions were 53.2% with 25 mg and 34.5% with 15 mg versus 10.4% with placebo over 12 weeks. JAMA Neurol • 2026-11-09 Original article: https://doi.org/10.1001/jamaneurol.2026.4141 CAR T-cell therapy shows promise in...
334 views -
[Articles] Safety, tolerability, and efficacy of bepranemab in people living with prodromal-to-mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2 trial https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00357-1/fulltext?rss=yes
391 views -
Information formatting in neuronal populations predicts differential functional contributions to behavior https://www.nature.com/articles/s41593-026-02514-7
549 views -
Azetukalner in Adults With Focal Seizures Research Summary https://jamanetwork.com/journals/jamaneurology/fullarticle/2856387
631 views -
Mivocabtagene Autoleucel CD19 CAR T-Cell Therapy in SPS https://jamanetwork.com/journals/jamaneurology/fullarticle/2856388
572 views -
Azetukalner in Adults With Focal Seizures https://jamanetwork.com/journals/jamaneurology/fullarticle/2856389
468 views 1 Reposts -
RIMKLA-IgG Paraneoplastic Syndrome With Cerebellar Ataxia https://jamanetwork.com/journals/jamaneurology/fullarticle/2856390
487 views 1 Reactions 1 Reposts -
Arrival of CAR T-Cell Therapies for Stiff Person Syndrome https://jamanetwork.com/journals/jamaneurology/fullarticle/2856391
505 views 1 Reposts -
Author Correction: A genome-wide analysis of the shared genetic risk architecture of complex neurological and psychiatric disorders https://www.nature.com/articles/s41593-026-02536-1
940 views -
Editorial Expression of Concern: NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans https://www.nature.com/articles/s41593-026-02534-3
1,050 views
-
Serotonin signaling enhances phagocytosis by brain macrophages through Htr2b and alleviates brain injury after stroke https://www.nature.com/articles/s41593-026-02482-y
1,530 views -
Circuit mechanisms for disentangled representations and generalization in the hippocampus https://www.nature.com/articles/s41593-026-02491-x
1,340 views 1 Reactions -
Toward Coordinated Systems of Care for TIA—The Role and Scope of EDs https://jamanetwork.com/journals/jamaneurology/fullarticle/2855738
1,080 views -
Single-neuron encoding of rapidly learned visual information reshapes human perception https://www.nature.com/articles/s41593-026-02496-6
1,080 views -
Editorial Expression of Concern: NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans https://www.nature.com/articles/s41593-026-02534-3
1,050 views -
Stimulus-specific recruitment of human amygdala neurons predicts episodic memory encoding success https://www.nature.com/articles/s41593-026-02493-9
1,030 views -
Publisher Correction: Network geometry shapes the transformation of task representations across the human cortex https://www.nature.com/articles/s41593-026-02530-7
1,020 views -
A multi-institutional investigation of psilocybin’s effects on mouse behavior https://www.nature.com/articles/s41593-026-02500-z
983 views 1 Reactions -
Author Correction: A genome-wide analysis of the shared genetic risk architecture of complex neurological and psychiatric disorders https://www.nature.com/articles/s41593-026-02536-1
940 views -
JAMA Neurology Editorial Fellowship https://jamanetwork.com/journals/jamaneurology/fullarticle/2856178
912 views
Questions about Neurology Updates
How many subscribers does Neurology Updates have?
Neurology Updates (@neurology_updates) has 16,751 subscribers as of November 12, 2026.
How many people see a post on Neurology Updates?
A typical post gets about 520 views within 24 hours, roughly 3% of its subscribers (the ERR).
What is Neurology Updates about?
It is listed in Health, and posts mostly in English. The channel describes itself as: “All the atest articles, research and news from worlds leading Neurology Journals. Discussion group https://t.me/Professional_Medical_Discussion”
Where does Neurology Updates rank?
By subscribers it is #58 in Health, #1,301 among English channels, #1,585 worldwide.
Does Neurology Updates post ads?
None of its 28 posts in the last 30 days carried an ad label such as #ad or Sponsored. Unlabelled promotions can’t be detected.
When does Neurology Updates post?
Most often on Monday, around 13:00 UTC. It publishes about 2 posts a day.
Statistics updated 34 minutes ago.